The World Health Organization declared a Public Health Emergency of International Concern (PHEIC) on Friday after epidemiological evidence confirmed limited but sustained human-to-human transmission of highly pathogenic avian influenza H5N1 in three countries — a development that global health officials have described as “the moment we have been preparing for and dreading simultaneously.”
What Has Changed
H5N1 avian influenza has circulated in birds since 1996 and has caused sporadic human infections since 2003 — predominantly through direct contact with infected poultry. The case fatality rate in confirmed human cases has historically been approximately 60%, making it the most lethal respiratory pathogen ever to threaten pandemic status.
What changed in February 2026 was the emergence of a novel H5N1 clade — 2.3.4.4b.12 — with three specific mutations in the polymerase complex that appear to confer limited ability to transmit between humans sharing close, sustained household contact. The mutations were simultaneously detected in case clusters in Hanoi, Vietnam; West Java, Indonesia; and Gharbia Governorate, Egypt.
Current Case Counts
As of the WHO’s emergency declaration:
- Confirmed human cases: 847 across 11 countries
- Deaths: 312 (case fatality rate 36.8% — lower than historical H5N1 but significantly higher than seasonal influenza)
- Confirmed human-to-human transmission clusters: 23
- Secondary attack rate within households: 8–12%
“The secondary attack rate remains low and the virus has not yet acquired efficient human-to-human transmission. But the direction of travel is clear and the window for containment is narrowing.”
— Dr. Tedros Adhanom Ghebreyesus, WHO Director-General
Vaccine Preparedness
Moderna announced that its mRNA H5N1 vaccine candidate (mRNA-1018) — which had been in Phase 2 trials since 2024 — demonstrated 94% efficacy against the 2.3.4.4b lineage in an interim analysis. Emergency use authorisation has been requested in the United States, European Union, and India.
Global stockpiles of pre-pandemic H5N1 vaccines (approximately 900 million doses under the WHO’s pandemic influenza preparedness framework) are being mobilised, though most target older H5N1 clades and their efficacy against the new variant is uncertain.
India’s Preparedness
India’s Ministry of Health and Family Welfare activated the National Influenza Pandemic Preparedness Plan on Thursday, requiring mandatory reporting of all severe acute respiratory infections with poultry exposure. The Serum Institute of India and Bharat Biotech have received government contracts to accelerate domestic H5N1 vaccine production.
What the Public Should Know
The current risk to the general public in non-affected countries remains low. No cases have been linked to international travel from non-endemic regions. Avoid contact with sick or dead birds, cook poultry thoroughly, and follow standard respiratory hygiene. Annual seasonal influenza vaccination does not protect against H5N1 but reduces the risk of co-infection — which experts believe could accelerate viral reassortment.
Leave a Reply